Cipla Latest News and Updates

Financial Performance and Board Decisions Quarterly Results: Cipla reported its financial results for the quarter ending June 30, 2025 (Q1 FY26). The company's consolidated net profit for this quarter rose by 10% to ₹1,298 crore, with revenue growing to ₹6,957 crore, primarily boosted by performance in the India and Africa markets. Upcoming Board Meeting: A Board Meeting is scheduled for October 30, 2025, to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2025 (Q2 FY26). Regulatory and Manufacturing Updates USFDA Status: Cipla's manufacturing facility in Bommasandra, India, received a VAI (Voluntary Action Indicated) classification from the USFDA in August 2025. This classification suggests that any observations noted during the inspection are minor and do not require further regulatory action. Product Recall: In a regulatory development, Cipla initiated a recall of over 20,000 packs of an inhalation drug in the U.S. market, as per the U.S. Food and Drug Administration (USFDA). New Products and Business Strategy New Launches: Cipla launched Huena, which is India's first non-antibiotic drug designed to fight recurrent urinary tract infections (UTI). Strategic Investment: The company announced agreements for an investment in Optionally Convertible Preference Shares of iCaltech Innovations to strengthen its respiratory device portfolio and overall respiratory market presence. Market Focus: Cipla is exploring entry into India's rapidly expanding weight management market and is also looking at new customer deals and markets for products manufactured at its facility in China.